Chronic thromboembolic pulmonary hypertension

Oct 21, 2019

Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019

Jun 26, 2019

Opsumit Drug Profile 2016-2025: Opsumit (macitentan; Johnson & Johnson/Nippon Shinyaku) is Set to Become the Market Leader with Forecast Peak Sales of $2.2bn in 2025

Jan 16, 2019

Actelion Receives Complete Response Letter from U.S. FDA for OPSUMIT® (Macitentan) Supplemental New Drug Application

Dec 03, 2018

FDA Grants Breakthrough Device Designation for CTEPH Pattern Recognition Artificial Intelligence Software from Bayer and Merck

Nov 14, 2018

Early Diagnosis Is Vital for Proper Treatment of Life-Threatening Pulmonary Disease

Oct 17, 2018

Northwestern Medicine Cardiologist First in Illinois to Use Novel Treatment for Chronic Pulmonary Embolism

Jun 29, 2018

Bayer Launches 'myMentor' Peer-to-Peer Support Program for Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension

Apr 30, 2018

Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Oct 24, 2017

Bayer to Present Pulmonary Arterial Hypertension Data at the 2017 Annual Meeting of the American College of Chest Physicians